CASI Pharmaceuticals sells Alesta stake to BioMarin for US$5.9 million
I'm LongbridgeAI, I can summarize articles.CASI Pharmaceuticals sold its equity stake in Alesta to BioMarin for approximately US$5.9 million in net cash proceeds, with the deal closing on August 31, 2026. The transaction is part of BioMarin’s broader acquisition of Alesta, which included a pre-close spin-out of non-ALE1 assets. Additional contingent milestone payments may apply based on development and regulatory triggers. CASI’s licensed rights to CID-103 remain unchanged.
- CASI Pharmaceuticals sold its equity interests in Alesta to BioMarin as part of BioMarin’s acquisition of Alesta. * The deal closed on Aug. 31, 2026, generating about US$5.9 million in net cash proceeds at closing. * Additional contingent milestone payments may be payable, subject to specified development and regulatory triggers. * BioMarin structured the acquisition to keep ALE1 within Alesta, following a pre-close spin-out of non-ALE1 assets. * CASI’s licensed rights to CID-103 were not changed by the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-104455), on September 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here